[Rectal carcinoma. Optimizing treatment by neoadjuvant and adjuvant therapy?]

Area of Science:

• Oncology
• Surgical Oncology
• Radiation Oncology

Context:

• Total mesorectal excision (TME) is a standard surgical procedure for rectal cancer.
• TME improves outcomes by controlling compartmental disease.
• Surgical radicality can be compromised by large, ventrally located rectal tumors due to their eccentric position within perirectal fat.

Purpose:

• To evaluate the efficacy of neoadjuvant treatment in improving outcomes for rectal cancer patients with challenging tumor locations.
• To assess the role of combined chemoradiotherapy in enhancing surgical radicality and reducing recurrence rates in specific rectal cancer cases.

Summary:

• Neoadjuvant treatment, involving radiotherapy doses of 45-54 Gy and 5-fluorouracil (5-FU) based chemotherapy, appears beneficial for rectal cancer with large ventral tumors.
• This multimodal approach aims to improve surgical outcomes by potentially increasing resectability and achieving clear margins.
• The strategy is intended to minimize local recurrence and distant metastases, thereby improving overall patient prognosis.

Impact:

• This approach may offer a better outcome for patients with large, ventrally located rectal tumors where standard TME might be insufficient.
• It highlights the importance of tailored neoadjuvant strategies in optimizing rectal cancer management.
• Potential reduction in local recurrence and distant metastases could lead to improved long-term survival rates for this patient subgroup.